Literature DB >> 25756206

Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease.

N Rydz1, J Grabell2, D Lillicrap1, P D James2.   

Abstract

In a normal population, VWF plasma levels (VWF:Ag) and VWF activity (VWF:RCo) increase by approximately 0.17 and 0.15 IU mL(-1) per decade, but the influence of age is unknown in patients with type 1 von Willebrand disease (VWD). In a retrospective cohort study, the medical records of 31 type 1 VWD patients over the age of 30, who had been followed for ≥5 years, were reviewed for baseline clinical data and previously performed VWF:Ag, VWF:RCo and factor VIII levels ( FVIII: C). VWF multimer analysis was normal in 28/31 cases performed. Mean age at diagnosis was 33 (range 16-60 years), and duration of follow-up ranged from 5 to 26 years (mean 11 years). Patients had 2-10 time points of VWD testing (mean of 5.2). The mean VWF:Ag, VWF:RCo and FVIII: C at time of diagnosis were 0.44 IU mL(-1) 0.34 IU mL(-1) and 0.75 IU mL(-1) . At last follow-up, the mean VWF:Ag, VWF:RCo and FVIII: C were significantly increased to 0.71 IU L(-1) , 0.56 IU mL(-1) and 0.90 IU mL(-1) (P ≤ 0.001, <0.001, and 0.0081 respectively). Here 18/31 patients had VWF:Ag, VWF:RCo and FVIII: C levels that increased into the normal range. The rate of change in VWF:Ag, VWF:RCo and FVIII was 0.30 IU mL(-1) (0.21-0.39, CI 95%, P < 0.0001), 0.20 IU mL(-1) per decade (0.13-0.27, CI 95%, P = 0.0001) and 0.20 IU mL(-1) (0.11-0.29, CI 95%, P = 0.0011). Patients with type 1 VWD experience age-related increases to VWF:Ag and VWF:RCo which can result in normalization of VWF levels. Further studies are required to determine if the bleeding phenotype resolves with the increases in VWF:Ag and VWF:RCo levels.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  ageing; bleeding; haemostasis; von Willebrand Disease

Mesh:

Substances:

Year:  2015        PMID: 25756206      PMCID: PMC4678413          DOI: 10.1111/hae.12664

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  29 in total

Review 1.  Impact, diagnosis and treatment of von Willebrand disease.

Authors:  J E Sadler; P M Mannucci; E Berntorp; N Bochkov; V Boulyjenkov; D Ginsburg; D Meyer; I Peake; F Rodeghiero; A Srivastava
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

2.  Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive.

Authors:  R A Kadir; D L Economides; C A Sabin; D Owens; C A Lee
Journal:  Thromb Haemost       Date:  1999-11       Impact factor: 5.249

3.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

4.  Aging, physical conditioning, and exercise-induced changes in hemostatic factors and reaction products.

Authors:  P J van den Burg; J E Hospers; W L Mosterd; B N Bouma; I A Huisveld
Journal:  J Appl Physiol (1985)       Date:  2000-05

5.  Fibrinogen and risk of cardiovascular disease. The Framingham Study.

Authors:  W B Kannel; P A Wolf; W P Castelli; R B D'Agostino
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

6.  Von Willebrand factor in Italian centenarians.

Authors:  Raffaella Coppola; Daniela Mari; Antonella Lattuada; Claudio Franceschi
Journal:  Haematologica       Date:  2003-01       Impact factor: 9.941

7.  Health status and health-related quality of life associated with von Willebrand disease.

Authors:  Ronald D Barr; Julia Sek; John Horsman; William Furlong; Mahassen Saleh; Mohan Pai; Irwin Walker
Journal:  Am J Hematol       Date:  2003-06       Impact factor: 10.047

8.  Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  M G Conlan; A R Folsom; A Finch; C E Davis; P Sorlie; G Marcucci; K K Wu
Journal:  Thromb Haemost       Date:  1993-09-01       Impact factor: 5.249

9.  Protein C, antithrombin III and plasminogen: effect of age, sex and blood group.

Authors:  G Dolan; K Neal; P Cooper; P Brown; F E Preston
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

10.  Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause.

Authors:  L Balleisen; J Bailey; P H Epping; H Schulte; J van de Loo
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

View more
  23 in total

1.  Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Authors:  Veronica H Flood; Pamela A Christopherson; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Daniel B Bellissimo; Rupa A Udani; Mahua Dasgupta; Raymond G Hoffmann; Margaret V Ragni; Amy D Shapiro; Jeanne M Lusher; Steven R Lentz; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Marilyn J Manco-Johnson; Ralph A Gruppo; Lisa N Boggio; Kate T Montgomery; Anne C Goodeve; Paula D James; David Lillicrap; Ian R Peake; Robert R Montgomery
Journal:  Blood       Date:  2016-02-09       Impact factor: 22.113

2.  Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?

Authors:  Mariachiara Borghi; Giuseppe Guglielmini; Anna Maria Mezzasoma; Emanuela Falcinelli; Loredana Bury; Marco Malvestiti; Paolo Gresele
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

3.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

4.  The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease.

Authors:  Craig D Seaman; Margaret V Ragni
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-06       Impact factor: 2.389

5.  Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.

Authors:  S Albánez; K Ogiwara; A Michels; W Hopman; J Grabell; P James; D Lillicrap
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

6.  Perioperative management of patients with von Willebrand disease.

Authors:  James S O'Donnell; Michelle Lavin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 7.  New treatment approaches to von Willebrand disease.

Authors:  Michelle Lavin; James S O'Donnell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

8.  Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease.

Authors:  Mariya H Apostolova; Craig D Seaman; Diane M Comer; Jonathan G Yabes; Margaret V Ragni
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-21       Impact factor: 2.389

Review 9.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

Review 10.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.